Related Experiment Video
Updated: May 12, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Case Report: Short-course defibrotide combined with eculizumab for TA-TMA.
Yan Yan1, Xiaoning Li1, Linyu Li1
1Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan, China.
Frontiers in Immunology
|May 11, 2026
Summary
This case study highlights a novel short-course combination therapy for transplantation-associated thrombotic microangiopathy (TA-TMA). Defibrotide and eculizumab showed efficacy in treating TA-TMA after hematopoietic stem cell transplantation.
Area of Science:
- Hematology
- Oncology
- Transplantation Medicine
Background:
- Transplantation-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic stem cell transplantation (HSCT).
- Current treatment options for TA-TMA are limited, and its underlying mechanisms remain unclear.
- This report focuses on a patient with acute myeloid leukemia (AML) who developed TA-TMA post-allogeneic HSCT.